peace, maybe revenue might fall in line with your thoughts, but:
"Clinical Trials -
Double cost estimates & extend time frames by 12 months"
I'll put money on that not happening
ANP has always delivered under budget and on time or before in the past, and I expect that to remain the case
However, as you said, yes it's all speculation, as is the broad generalisation from a biotech analyst
Ann: Share Purchase Plan Closes , page-33
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |